Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
There's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis.
Overview
Like most other up-and-coming biopharma companies, CRISPR Therapeutics (NASDAQ: CRSP) brings both risk and reward to the table. This particular name, however, may bring less risk than it seems at first blush, and perhaps even more reward.
CRISPR Therapeutics is a developer of gene therapies for disease, by the way. Specifically, the company's founders figured out how to cut a damaged segment out of a DNA strand and replace it with a corrected one. It even has an approved therapy on the market, with more in the works.
Details
As you might imagine, though, such development isn't cheap. Like other newcomers to the biopharma business, CRISPR Therapeutics is consuming cash at a pretty brisk clip.
Source
Originally published at www.fool.com.